Trial Profile
Effect of genetic polymorphism on response to adalimumab in Crohn's disease patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Feb 2016
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Crohn's disease
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- 09 Feb 2016 New trial record